Free Newsletter
AIDS drug researchers unveil a dramatic breakthrough
AIDS researchers have solved one of the most perplexing riddles that has stumped scientists in their 20-year-old hunt for effective therapies. After years of trial and error, a team of scientists in London has managed to unveil the structure of integrase, an enzyme the lethal virus uses to copy genetic material into DNA. The breakthrough may well pave the way for a new generation of AIDS drugs that are far more effective than those now in wide use.
The quest took more than four years and involved 40,000 experiments. The scientists eventually focused on an enzyme taken from the prototype foamy virus--which closely mimics HIV--in order to create a three-dimensional crystal structure of the target enzyme. And they could use that model to actually see, for the first time, how HIV drugs inhibit the virus.
"When we started out, we knew that the project was very difficult, and that many tricks had already been tried and given up by others long ago," says Peter Cherepanov of Imperial College London. "Therefore, we went back to square one and started by looking for a better model of HIV integrase, which could be more amenable for crystallization."
Now that the scientists have this key, they can use it to develop drugs that are less likely to spur resistance from HIV. AIDS killed some 2 million people in 2008, and the HIV virus infected another 2.7 million.
- check out the Imperial College release
- here's the report from the CBC
Related Articles:
Breakthrough offers new target for HIV researchers
HIV/AIDS vax 'leapfrogs' immune system
Gene therapy could offer AIDS cure
Comments
We have been working with Merck on the analysis of drug resistance to their new integrase inhibitor (Isentress or raltegravir). Drug resistance is a big issue for anti-HIV drugs because of the virus rapid rate of replication.
There is a drug on the market that targets integrase, made by Merck. This advance is good news, but hardly could be called a breakthrough since the whole point of achieving it has already been done - several really good integrase inhibitos already exist.
*Both these quotes are from my contacts in my database and I thought worth sharing .
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities

SHARE
WITH: